Industry Features

1.Integration of multiple industries

The medical industry,an important part of China's national economy, is an industry that combines traditional industries with modern industries and integrates primary, secondary, and tertiary industries.

2.Vital bearing on the national economy and people's well being

As a part of the medical and health system, the industry plays a very important role in protecting people's health, improving life quality, and promoting economic development and social progress in terms of family planning, epidemic prevention, disaster relief, military preparations, etc.

3.Input-output risk

The medical industry features high technologies with high risks and high returns, and costly investment with long cycles.

Current Situation

A. Prominent and pressing problem: too many small companies, but few leading companies.

Most enterprises are not only small in scale, poor in production conditions and outdated in technology and equipment, but also low in management level and decentralized in business layout. The production concentration of enterprises is far lower than that of advanced countries.

B. An enterprise-centered technological innovation system to be formed.

New products without China's independent intellectual property rights, slow product updates, severe duplication, traditional Chinese medicine (TCM) technologies and preparations’ incompetence in the international market, all these are to be addressed urgently.

C. The quality and performance of medical equipment products are poor, and the structure of import and export is unreasonable.

Most of the medical device products that China can produce are conventionally low and medium-end products with low added value, making the export proportion of high-tech products relatively low, while most of the high-end, sophisticated, and cutting-edge medical devices and new practical medical equipment required in clinical practice need to be imported.

D. Strictly regulated domestic and foreign markets with standards non-unified.

For biopharmaceuticals and medical devices to be exported to the United States, Europe, or other countries/regions, they need to meet the regulations of these countries and/or regions, and obtain their certifications, such as the GNP certification of the United States, the EU-GMP certification, etc.

Industry Demand

1. For domestic biological and pharmaceutical companies, on the one hand, they must face competition in the domestic market, and on the other hand, they must meet the compliance requirements of regulatory authorities. Export companies also face international competition and international compliance supervision. At the same time, to meet the needs of improving the competitiveness of enterprises in domestic and foreign markets, domestic enterprises are actively carrying out digital transformation to achieve the purpose of reducing costs and increasing efficiency, and to gain a firm foothold in fierce market competition and strict regulatory environment.

 2. A sustainable health technology innovation mechanism and talent guarantee mechanism are to be established: The medical industry features high technologies with high risks and high returns, and high investment with long cycles, which is determined by soaring costs of new product development, demanding requirements for the construction of pharmaceutical plants, and high-level configurations of equipment and instruments.

 3. The need for industrial model adjustment and upgrading: In the past two years, the outbreak of the Covid-19 pandemic has brought not only rare opportunities for the development of global biopharmaceutical companies, but also unprecedented challenges. Due to the needs of epidemic prevention and control, the demand for medicines and medical devices related to the treatment of the new pneumonia has shown explosive growth, bringing huge profits to related companies. At the same time, it has also increased the research and development, production and manufacturing capabilities of related medicines and medical device companies. The ability of compliance management has been tested unprecedentedly. The adjustment and upgrading of the traditional industrial model to break through the bottlenecks of capabilities has become the best path for biopharmaceutical companies to quickly form a competitive advantage.

In view of the issues and needs, industry credit package with full case plans consists of two stages:

Stage One: Corporate compliance for healthy development of a company

1. Production and operation compliance for optimization of external credits.
2. Establishment of internal management with talent building system.
3. Financial and tax compliance for better corporate integration.

Advanced AEO Certification to help enterprises achieve economic benefits growing from 1 to N.

1. Implement safety management and compliance management based on Stage One.
2. Connect with the Customs to supplement the details of internal control, compliance with laws and regulations, financial status, and trade security.
3、3. Materialize thoroughly the transformation from enterprise informatization to digitalization.
HUAREN integrates the data and processes from diverse factors related to production, such as personnel.